Portal de Periódicos da CAPES

AstraZeneca (AZD1222) COVID‐19 vaccine‐associated adverse drug event: A case report

2021; Wiley; Volume: 93; Issue: 10 Linguagem: Inglês

10.1002/jmv.27175

1096-9071

Marco Capassoni, Sheyda Ketabchi, Angelo Cassisa, R. Caramelli, Anna A. Molinu, Felice Galluccio, Serena Guiducci,

Peripheral Neuropathies and Disorders

Journal of Medical VirologyVolume 93, Issue 10 p. 5718-5720 LETTER TO THE EDITOR AstraZeneca (AZD1222) COVID-19 vaccine-associated adverse drug event: A case report Marco Capassoni, Corresponding Author Marco Capassoni [email protected] orcid.org/0000-0003-2209-4450 Department of Clinical and Experimental Rheumatology, University of Florence, Florence, Italy Department of Rheumatology, Azienda Ospedaliero Universitaria Careggi, Florence, Italy Correspondence Marco Capassoni, Department of Clinical and Experimental Rheumatology, University of Florence, Florence, Italy. Email: [email protected]Search for more papers by this authorSheyda Ketabchi, Sheyda Ketabchi Department of Anatomopathology, Ospedale San Giovanni di Dio, Florence, ItalySearch for more papers by this authorAngelo Cassisa, Angelo Cassisa Department of Anatomopathology, Ospedale San Giovanni di Dio, Florence, ItalySearch for more papers by this authorRiccardo Caramelli, Riccardo Caramelli orcid.org/0000-0002-7110-040X Department of Neurophysiopathology, Azienda Ospedaliero Universitaria Careggi, Florence, ItalySearch for more papers by this authorAnna A. Molinu, Anna A. Molinu Dermatology, Istituto Ortopedico Toscano, Florence, ItalySearch for more papers by this authorFelice Galluccio, Felice Galluccio orcid.org/0000-0001-7485-471X Department of Rheumatology, Azienda Ospedaliero Universitaria Careggi, Florence, ItalySearch for more papers by this authorSerena Guiducci, Serena Guiducci orcid.org/0000-0003-2722-6475 Department of Clinical and Experimental Rheumatology, University of Florence, Florence, Italy Department of Rheumatology, Azienda Ospedaliero Universitaria Careggi, Florence, ItalySearch for more papers by this author Marco Capassoni, Corresponding Author Marco Capassoni [email protected] orcid.org/0000-0003-2209-4450 Department of Clinical and Experimental Rheumatology, University of Florence, Florence, Italy Department of Rheumatology, Azienda Ospedaliero Universitaria Careggi, Florence, Italy Correspondence Marco Capassoni, Department of Clinical and Experimental Rheumatology, University of Florence, Florence, Italy. Email: [email protected]Search for more papers by this authorSheyda Ketabchi, Sheyda Ketabchi Department of Anatomopathology, Ospedale San Giovanni di Dio, Florence, ItalySearch for more papers by this authorAngelo Cassisa, Angelo Cassisa Department of Anatomopathology, Ospedale San Giovanni di Dio, Florence, ItalySearch for more papers by this authorRiccardo Caramelli, Riccardo Caramelli orcid.org/0000-0002-7110-040X Department of Neurophysiopathology, Azienda Ospedaliero Universitaria Careggi, Florence, ItalySearch for more papers by this authorAnna A. Molinu, Anna A. Molinu Dermatology, Istituto Ortopedico Toscano, Florence, ItalySearch for more papers by this authorFelice Galluccio, Felice Galluccio orcid.org/0000-0001-7485-471X Department of Rheumatology, Azienda Ospedaliero Universitaria Careggi, Florence, ItalySearch for more papers by this authorSerena Guiducci, Serena Guiducci orcid.org/0000-0003-2722-6475 Department of Clinical and Experimental Rheumatology, University of Florence, Florence, Italy Department of Rheumatology, Azienda Ospedaliero Universitaria Careggi, Florence, ItalySearch for more papers by this author First published: 02 July 2021 https://doi.org/10.1002/jmv.27175Citations: 24Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. REFERENCES 1Akinosoglou K, Tzivaki I, Marangos M. Covid-19 vaccine and autoimmunity: Awakening the sleeping dragon. Clin Immunol. 2021; 226:108721. https://doi.org/10.1016/j.clim.2021.108721 10.1016/j.clim.2021.108721 CASPubMedWeb of Science®Google Scholar 2Talotta R. Do COVID-19 RNA-based vaccines put at risk of immune-mediated diseases? In reply to "potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases". Clin Immunol. 2021; 224:108665. 10.1016/j.clim.2021.108665 CASPubMedWeb of Science®Google Scholar 3Blumenthal KG, Freeman EE, Saff RR, et al. Delayed large local reactions to mRNA-1273 vaccine against SARS-CoV-2. N Engl J Med. 2021; 384(13): 1273-1277. https://doi.org/10.1056/NEJMc2102131 10.1056/NEJMc2102131 PubMedWeb of Science®Google Scholar 4von den Driesch P. Sweet's syndrome (acute febrile neutrophilic dermatosis). J Am Acad Dermatol. 1994; 31(4): 535-556. https://doi.org/10.1016/s0190-9622(94)70215-2 10.1016/S0190-9622(94)70215-2 PubMedWeb of Science®Google Scholar 5Su WP, Liu HN. Diagnostic criteria for Sweet's syndrome. Cutis. 1986; 37(3): 167-174. CASPubMedWeb of Science®Google Scholar 6Caso F, Costa L, Ruscitti P, et al. Could Sars-coronavirus-2 trigger autoimmune and/or autoinflammatory mechanisms in genetically predisposed subjects? Autoimmun Rev. 2020; 19(5):102524. https://doi.org/10.1016/j.autrev.2020.102524 10.1016/j.autrev.2020.102524 CASPubMedWeb of Science®Google Scholar 7Rodríguez Y, Novelli L, Rojas M, et al. Autoinflammatory and autoimmune conditions at the crossroad of COVID-19. J Autoimmun. 2020; 114:102506. https://doi.org/10.1016/j.jaut.2020.102506 10.1016/j.jaut.2020.102506 CASPubMedWeb of Science®Google Scholar Citing Literature Volume93, Issue10Special Issue on New coronavirus (2019‐nCoV or SARS‐CoV‐2) and the outbreak of the respiratory illness (COVID‐19): Part‐XVOctober 2021Pages 5718-5720 ReferencesRelatedInformation